Extracellular Vesicles to Predict Outcomes After Transcatheter Aortic Valve Implantation – a Prospective, Multicenter Cohort Study

• DOI: 10.1007/s12265-024-10521-x
• Publication Date: 2024-05-28T21:03:06Z
• Authors: Radosław Wilimski; Jan Budzianowski; Michał Łomiak; Anna Olasińska-Wi...; Katarzyna Pieniak; Szymon Jędrzejczyk; Olaf Domaszk; Magdalena Chudzik; Krzysztof J. Fili...; Jarosław Hiczkiewicz; Wojciech Faron; Tomasz Urbanowicz; Marek Jemielity; Marek Grygier; Marcin Grabowski; Mariusz Kuśmierczyk; Bartosz Rymuza; Zenon Huczek; Janusz Kochman; Edwin van der Pol; Rienk Nieuwland; Aleksandra Gąsecka
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Original Article

Abstract

Introduction Transcatheter aortic valve implantation (TAVI) is an established treatment for aortic stenosis (AS) in patients at intermediate and high surgical risk. Circulating extracellular vesicles (EVs) are nanoparticles involved in cardiovascular diseases. We aimed to (i) determine the effect of TAVI on plasma concentrations of five EV subtypes and (ii) evaluate the predictive value of EVs for post-TAVI outcomes.

Methods Blood samples were collected 1 day before TAVI and at hospital discharge. Concentrations of EVs were evaluated using flow cytometry.

Results Concentration of leukocytes EVs decreased after TAVI, compared to the measurement before (p = 0.008). Among 123 patients discharged from the hospital, 19.5% experienced MACCE during the median of 10.3 months. Increased pre-TAVI concentration of phosphatidylserine-exposing EVs was an independent predictor of MACCE in multivariable analysis (OR 5.313, 95% CI 1.164–24.258, p = 0.031).

Conclusions Patients with increased pre-TAVI concentration of procoagulant, PS-exposing EVs have over fivefold higher odds of adverse outcomes.

Graphical Abstract